Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Nakata, Bunzo ^a   Amano, Ryosuke ^a   Nakao, Shigetomi ^a   Tamura, Tatsuro ^a   Shinto, Osamu ^a   Hirakawa, Toshiki ^a   Okita, Yoshihiro ^a   Yamada, Nobuya ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG WITHDRAWAL; HUMAN; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BLOOD; DRUG COMBINATION; DRUG INTERACTION; DRUG SCREENING; MIDDLE AGED; MOUSE; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PANCREAS TUMOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG INTERACTIONS; FLUOROURACIL; HUMANS; MICE; MICE, NUDE; MIDDLE AGED; OXONIC ACID; PANCREATIC NEOPLASMS; TEGAFUR; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949588366     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-15     Document Type: Article

References (19)

1. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. MJ Moore D Goldstein J Hamm A Figer JR Hecht S Gallinger HJ Au P Murawa D Walde RA Wolff D Campos R Lim K Ding G Clark T Voskoglou-Nomikos M Ptasynski W Parulekar National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol 2007 25 1960 1966 10.1200/JCO.2006.07.9525 17452677
2. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. T Shirasaka Y Shimamato H Ohshimo M Yamaguchi T Kato K Yonekura M Fukushima, Anti-Cancer Drugs 1996 7 548 557 10.1097/00001813-199607000-00010 8862723
3. A late phase II study of S-1 for metastatic pancreatic cancer. T Okusaka A Funakoshi J Furuse N Boku K Yamao S Ohkawa H Saito, Cancer Chemoth Pharm 2008 61 615 621 10.1007/s00280-007-0514-8
4. Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. K Nakamura T Yamaguchi T Ishihara A Kobayashi H Tadenuma K Sudo H Kato H Saisho, Br J Cancer 2005 92 2134 2139 10.1038/sj.bjc.6602644 15942632
5. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. H Ueno T Okusaka M Ikeda Y Ishiguro C Morizane J Matsubara J Furuse H Ishii M Nagase K Nakachi, Oncology 2005 69 421 427 10.1159/000089997 16319514
6. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. K Nakamura T Yamaguchi T Ishihara K Sudo H Kato H Saisho, Br J Cancer 2006 94 1575 1579 16721372
7. A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. H Ueno T Okusaka J Furuse K Yamao A Funakoshi N Boku S Ohkawa A Makimoto T Sato, J Clin Oncol 2007 25 Abst#4550 17194903
8. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and -fluoro - alanine after oral administration of S-1 following total gastrectomy. WY Kim B Nakata K Hirakawa, Cancer Sci 2007 98 1604 1608 10.1111/j.1349-7006.2007.00573.x 17683513
9. The detection of human pancreatic cancer-associated antigen in the serum of cancer patients. YS Chun JJL Ho YS Kim H Tanaka B Nakata A Hiura H Motoyoshi K Satake K Umeyama, Cancer 1987 60 1636 1643 10.1002/1097-0142(19871001)60: 7<1636::AID-CNCR28206007363.0.CO;2-C 3476183
10. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. HA Burris MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff, J Clin Oncol 1997 15 2403 2413 9196156
11. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. JL Abbruzzese R Grunewald EA Weeks D Gravel T Adams B Nowak S Mineishi P Tarassoff W Satterlee MN Raber, J Clin Oncol 1991 9 491 498 1999720
12. A phase II and pharmacokinetic trial of oral S-1 combined with gemcitabine (GEM) in patients with metastatic pancreatic cancer (MPC). K Nakamura T Yamaguchi T Ishihara K Sudo A Kobayashi H Tadenuma H Ishiguro H Saisho, J Clin Oncol 2005 23 Abst#4114
13. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. W Koizumi S Tanabe K Saigenji A Ohtsu N Boku F Nagashima K Shirao Y Matsumura M Gotoh, Br J Cancer 2003 89 2207 2212 10.1038/sj.bjc.6601413 14676796
14. Phase I and Pharmacokinetic Study of S-1 Combined with Weekly Paclitaxel in Patients with Advanced Gastric Cancer. K Fujitani H Narahara H Takiuchi T Tsujinaka E Satomi M Gotoh M Hirao H Furukawa T Taguchi, Oncology 2005 69 414 420 10.1159/000089996 16319513
15. Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. P Correale D Cerretani S Marsili D Pozzessere R Petrioli S Messinese M Sabatino F Roviello E Pinto G Francini G Giorgi, Eur J Cancer 2003 39 1547 1551 10.1016/S0959-8049(03)00361-7 12855261
16. Relationship between fluorouracil systemic exposure and tumor response and patients survival. G Milano MC Etienne N Renee A Thyss M Schneider A Ramaioli F Demard, J Clin Oncol 1994 12 1291 1295 8201391
17. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. S Madajewicz P Hentschel P Burns R Caruso J Fiore M Fried H Malhotra S Ostrow S Sugarman M Viola, J Clin Oncol 2000 18 3553 3557 11032598
18. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. J Pressacco B Mitrovski C Erlichman DW Hedley, Cancer Res 1995 55 1505 1508 7882359
19. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. S Nakahira S Nakamori M Tsujie S Takeda K Sugimoto Y Takahashi J Okami S Marubashi A Miyamoto Y Takeda H Nagano K Dono K Umeshita M Sakon M Monden, Anticancer Res 2008 28 179 186 18383843